A preliminary study of micro-RNAs as minimally invasive biomarkers for the diagnosis of prostate cancer patients
Open Access
- 23 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Experimental & Clinical Cancer Research
- Vol. 40 (1), 1-12
- https://doi.org/10.1186/s13046-021-01875-0
Abstract
A prostate cancer diagnosis is based on biopsy sampling that is an invasive, expensive procedure, and doesn’t accurately represent multifocal disease. To establish a model using plasma miRs to distinguish Prostate cancer patients from non-cancer controls, we enrolled 600 patients histologically diagnosed as having or not prostate cancer at biopsy. Two hundred ninety patients were eligible for the analysis. Samples were randomly divided into discovery and validation cohorts. NGS-miR-expression profiling revealed a miRs signature able to distinguish prostate cancer from non-cancer plasma samples. Of 51 miRs selected in the discovery cohort, we successfully validated 5 miRs (4732-3p, 98-5p, let-7a-5p, 26b-5p, and 21-5p) deregulated in prostate cancer samples compared to controls (p ≤ 0.05). Multivariate and ROC analyses show miR-26b-5p as a strong predictor of PCa, with an AUC of 0.89 (CI = 0.83–0.95;p < 0.001). Combining miRs 26b-5p and 98-5p, we developed a model that has the best predictive power in discriminating prostate cancer from non-cancer (AUC = 0.94; CI: 0,835-0,954). To distinguish between low and high-grade prostate cancer, we found that miR-4732-3p levels were significantly higher; instead, miR-26b-5p and miR-98-5p levels were lower in low-grade compared to the high-grade group (p ≤ 0.05). Combining miR-26b-5p and miR-4732-3p we have the highest diagnostic accuracy for high-grade prostate cancer patients, (AUC = 0.80; CI 0,69-0,873). Noninvasive diagnostic tests may reduce the number of unnecessary prostate biopsies. The 2-miRs-diagnostic model (miR-26b-5p and miR-98-5p) and the 2-miRs-grade model (miR-26b-5p and miR-4732-3p) are promising minimally invasive tools in prostate cancer clinical management.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (16862)
- Sapienza Università di Roma (RM11816430E896B2)
This publication has 33 references indexed in Scilit:
- Biomarkers in prostate cancer surveillance and screening: past, present, and futureTherapeutic Advances in Urology, 2013
- The complexity of prostate cancer: genomic alterations and heterogeneityNature Reviews Urology, 2012
- MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinomaMolecular Cancer, 2012
- A panel of five circulating microRNAs as potential biomarkers for prostate cancerThe Prostate, 2012
- Microfluidic-Based Multiplex qRT-PCR Identifies Diagnostic and Prognostic microRNA Signatures in the Sera of Prostate Cancer PatientsCancer Research, 2011
- The MicroRNA Spectrum in 12 Body FluidsClinical Chemistry, 2010
- Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of DiagnosisJNCI Journal of the National Cancer Institute, 2009
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008
- PSA Screening Among Elderly Men With Limited Life ExpectanciesJAMA, 2006
- Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1998